邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

减瘤性肾切除术在转移性肾细胞癌治疗中的应用

郑国洋,  张玉石,  李汉忠

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(5): 601-605
郑国洋, 张玉石, 李汉忠. 减瘤性肾切除术在转移性肾细胞癌治疗中的应用[J]. 协和医学杂志, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
引用本文: 郑国洋, 张玉石, 李汉忠. 减瘤性肾切除术在转移性肾细胞癌治疗中的应用[J]. 协和医学杂志, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
shu
Guo-yang ZHENG, Yu-shi ZHANG, Han-zhong LI. Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
Citation: Guo-yang ZHENG, Yu-shi ZHANG, Han-zhong LI. Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
shu

减瘤性肾切除术在转移性肾细胞癌治疗中的应用

doi: 10.3969/j.issn.1674-9081.2020.05.017

  • 中国医学科学院 北京协和医学院 北京协和医院泌尿外科，北京 100730

详细信息
    通讯作者:

    张玉石  电话：010-69152510，E-mail: zhangyushi@126.com

  • 中图分类号: R737.11; R692.9

Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma

  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 减瘤性肾切除术在细胞因子治疗时代一度被推荐用于体能状态良好的转移性肾细胞癌的治疗。近年来，虽然靶向治疗广泛应用，减瘤性肾切除术仍是转移性肾细胞癌治疗的重要组成部分。随着CARMENA和SURTIME两项前瞻性研究的发表，减瘤性肾切除术在转移性肾细胞癌中的应用价值被重新审视。本文重点结合上述两项研究的结果以及相关思考，对减瘤性肾切除术在转移性肾细胞癌中的应用进展进行综述。
    Abstract: In the interferon era, cytoreductive nephrectomy was recommended for the treatment of patients with good performance status that were diagnosed with metastatic renal cell carcinoma. In recent years, in spite of the wide application of targeted therapy, cytoreductive nephrectomy is still an important part of the treatment of metastatic renal cell carcinoma. With the publication of two prospective studies, CARMENA and SURTIME, the role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma should be revalued. Based on the results and related considerations of above two studies, we reviewed recent progress in the application of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    利益冲突  无
    • HTML全文
    • 参考文献(23)
  • [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69:7-34. doi:  10.3322/caac.21551
    [2] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63:11-30. doi:  10.3322/caac.21166
    [3] Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma[J]. Eur Urol, 2019, 75:74-84. doi:  10.1016/j.eururo.2018.08.036
    [4] Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J]. N Engl J Med, 2001, 345:1655-1659. doi:  10.1056/NEJMoa003013
    [5] Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial[J]. Lancet, 2001, 358:966-970. doi:  10.1016/S0140-6736(01)06103-7
    [6] Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol, 2004, 171:1071-1076. doi:  10.1097/01.ju.0000110610.61545.ae
    [7] Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era[J]. Int J Cancer, 2014, 134:2245-2252. doi:  10.1002/ijc.28553
    [8] 盛锡楠, 郭军.晚期肾癌:治疗进展及展望[J].协和医学杂志, 2019, 2:148-151. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_xhyx201902013&dbid=WF_QK
    [9] García-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis[J]. Investig Clin Urol, 2018, 59:2-9. doi:  10.4111/icu.2018.59.1.2
    [10] Bex A, Ljungberg B, van Poppel H, et al. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016[J]. Eur Urol, 2016, 70:901-905. doi:  10.1016/j.eururo.2016.07.005
    [11] Hanna N, Sun M, Meyer CP, et al. Survival analyses of Patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A National Cancer Data Base Study[J]. J Clin Oncol, 2016, 34:3267-3275. doi:  10.1200/JCO.2016.66.7931
    [12] Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Eur Urol, 2014, 66:704-710. doi:  10.1016/j.eururo.2014.05.034
    [13] Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy[J]. BJU Int, 2010, 106:218-223.
    [14] 郑克文, 李汉忠, 李永强.转移性肾癌靶向药物治疗的预后因素和相关模型[J].中国医学科学院学报, 2014, 36:450-453. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb201404018
    [15] Heng DY, Xie WL, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study[J]. Lancet Oncol, 2013, 14:141-148. doi:  10.1016/S1470-2045(12)70559-4
    [16] Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 379:417-427. doi:  10.1056/NEJMoa1803675
    [17] Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5:164-170. doi:  10.1001/jamaoncol.2018.5543
    [18] Silberstein JL, Adamy A, Maschino AC, et al. Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)[J]. BJU Int, 2012, 110:1276-1282. doi:  10.1111/j.1464-410X.2012.11103.x
    [19] Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery[J]. J Urol, 2012, 187:1548-1554. doi:  10.1016/j.juro.2011.12.075
    [20] Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma[J]. Eur Urol, 2014, 66:874-880. doi:  10.1016/j.eururo.2014.01.035
    [21] 郑国洋, 李汉忠, 张玉石.PD-1/PD-L1通路相关的肾癌免疫治疗研究进展[J].中华医学杂志, 2017, 97:958-960. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201712019
    [22] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373:1803-1813. doi:  10.1056/NEJMoa1510665
    [23] Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer[J]. Eur Urol, 2018, 73:311-315. doi:  10.1016/j.eururo.2017.11.016
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  233
  • HTML全文浏览量:  66
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-07-02
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！